Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC (NCT06726161)

🧪 Interventions in This Study

• RYZ801 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (13 Sites)

• Research Facility — Birmingham, Alabama
• Research Facility — Phoenix, Arizona
• Research Facility — Tucson, Arizona
• Research Facility — Orange, California
• Research Facility — Jacksonville, Florida
• Research Facility — Lexington, Kentucky
• Research Facility — Baltimore, Maryland
• Research Facility — Rochester, Minnesota
• Research Facility — Omaha, Nebraska
• Research Facility — New York, New York
• Research Facility — Houston, Texas
• Research Facility — Charlottesville, Virginia
• Research Facility — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (619) 657-0057

Email: clinicaltrials@rayzebio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hepatocellular Carcinoma (HCC)

• Streamlined Resin Y90 Radiation Segmentectomy for Small HCC — Chapel Hill, North Carolina
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE — Aurora, Colorado
• Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin — San Francisco, California
• Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. — Hamilton, Ontario
• Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant — London, Ontario
• Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 — Palo Alto, California

Explore by condition: All Hepatocellular Carcinoma (HCC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.